HCPLive

Related Tags

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
 
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
 
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Most Popular

Recommended Reading

Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.
Ibuprofen and acetaminophen are among the well-known ingredients found in pain relievers, but an unusual addition that works just as well as existing medications may be making its way onto store shelves.
Developing drugs for conditions like multiple sclerosis takes a long time and a considerable amount of research. How the drugs are used, and changed is a delicate process undertaken between doctors and their patients over the course of the disease.
Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.
$vAR$